Revvity (RVTY)
NYSE:RVTY
Want to see RVTY full AI Analyst Report?
Top Page
Revvity
(NYSE:RVTY)
Select Model
Select Model
Rating:62Neutral
Price Target:
$92.00
▼(-2.09% Downside)
Action:ReiteratedDate:05/05/26
The score is anchored by solid financial quality—particularly strong, improving free cash flow and manageable leverage—supported by a constructive earnings update with margin improvement initiatives. These positives are tempered by weak technicals (price below key moving averages with negative MACD) and a relatively rich valuation with minimal dividend support.
Positive Factors
Strong free cash flow
Revvity's consistent positive free cash flow — highlighted by a $115M Q1 result and ~97% conversion — underpins durable financial flexibility. Reliable cash conversion supports reinvestment in R&D, acquisitions, buybacks, and debt paydown, strengthening long-term optionality.
Negative Factors
Margin compression
A multi-year downshift in operating and net margins materially reduces earnings resilience and return on capital. Even with gross margin healthy, compressed operating profit limits the company's ability to finance growth or absorb shocks, constraining long-term profitability improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow
Revvity's consistent positive free cash flow — highlighted by a $115M Q1 result and ~97% conversion — underpins durable financial flexibility. Reliable cash conversion supports reinvestment in R&D, acquisitions, buybacks, and debt paydown, strengthening long-term optionality.
Read all positive factors
Revvity (RVTY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.67B
Dividend Yield0.29%
Average Volume (3M)934.14K
Price to Earnings (P/E)27.9
Beta (1Y)0.94
Revenue Growth3.67%
EPS Growth-12.98%
CountryUS
Employees11,000
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)2.08
Shares Outstanding111,803,330
10 Day Avg. Volume819,928
30 Day Avg. Volume934,140
Financial Highlights & Ratios
PEG Ratio-3.32
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue4.48
Enterprise Value/Gross Profit8.94
Enterprise Value/Ebitda16.73
Forecast
1Y Price Target
$102.88Price Target Upside9.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)5.4
Revenue Forecast (FY)$2.98B
Revvity Business Overview & Revenue Model
Company Description
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solu...
How the Company Makes Money
Revvity generates revenue primarily by selling (1) instruments and related hardware platforms, (2) recurring consumables and reagents that run on those platforms, (3) software/informatics products, and (4) services such as maintenance, support, an...
Revvity Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down where sales come from around the world, revealing dependence on particular markets and exposure to regional growth or regulatory risk. Shifts between regions signal where Revvity is gaining share or facing headwinds and can affect currency and supply‑chain sensitivity.
Breaks down where sales come from around the world, revealing dependence on particular markets and exposure to regional growth or regulatory risk. Shifts between regions signal where Revvity is gaining share or facing headwinds and can affect currency and supply‑chain sensitivity.
Data provided by:
The Fly
The FlyRevvity Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| Next Earnings Date:Aug 03, 2026
Earnings Call Sentiment Positive
The call conveyed a generally positive tone driven by a better-than-expected Q1 (organic growth, margin and EPS beats), strong cash conversion, healthy software ARR trends, and a strategic decision to divest a underperforming China diagnostics business that should improve longer-term margins and growth. Near-term cautions include China market weakness, Q2 software cadence volatility, a ~$0.15 EPS headwind in 2026 from the divestiture (with proceeds not realized until 2027), and reduced FX tailwinds. Management emphasized operational cost initiatives and expected margin expansion into the second half of the year and into 2027, supporting an upbeat long-term outlook despite the identified near-term risks.Positive Updates
Quarterly Revenue and Organic Growth
Generated total revenue of $711 million in Q1; reported total-company organic growth of 3% in the quarter. On a pro forma basis (excluding China immunodiagnostics), Q1 revenue would have been $687 million and pro forma organic growth would have been 6%.
Negative Updates
China Diagnostics Market Pressures
China immunodiagnostics faced persistent policy-induced headwinds and meaningful declines (China region down double digits overall), prompting the planned divestiture. APAC organic growth declined mid-single digits driven by China weakness.
Read all updates
Q1-2026 Updates
Positive
Negative
Quarterly Revenue and Organic Growth
Generated total revenue of $711 million in Q1; reported total-company organic growth of 3% in the quarter. On a pro forma basis (excluding China immunodiagnostics), Q1 revenue would have been $687 million and pro forma organic growth would have been 6%.
Read all positive updates
Company Guidance
Revvity updated its 2026 pro forma guidance (which excludes the China immunodiagnostics business) to organic growth of 3%–4%, pro forma adjusted operating margin of 28.4% (about 40 bps above prior outlook), and pro forma adjusted EPS of $5.20–$5.30 (a net ~$0.15 reduction versus prior, reflecting the planned divestiture and a $0.05 operational benefit), with total revenue now expected at $2.81B–$2.84B; key drivers called out include a ~50 bp FX tailwind and ~75 bp benefit from the ACD/Labs acquisition, and the divestiture removes roughly 4.5% of prior expected revenue (making China ~8%–9% of company revenue, ~7% Life Sciences). Management also gave quarter-level guidance: Q2 pro forma organic growth 2%–3%, pro forma revenue $699M–$707M, pro forma Q2 margin ~27% and Q2 EPS ~23% of the full-year outlook (≈$1.20–$1.22); for context, Q1 reported results were $711M revenue, 3% organic growth (pro forma Q1 revenue $687M, 6% pro forma organic), adjusted operating margin 23.6% (24% pro forma), adjusted EPS $1.06 ($1.04 pro forma), free cash flow $115M (97% conversion), net debt/EBITDA 2.8x, and ~112M diluted shares.Revvity Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
70
Positive
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.86B | 2.76B | 2.75B | 3.31B | 3.83B |
| Gross Profit | 1.52B | 1.32B | 1.32B | 1.76B | 2.28B |
| EBITDA | 662.72M | 840.25M | 713.56M | 1.18B | 1.62B |
| Net Income | 241.68M | 295.83M | -118.38M | 569.18M | 943.16M |
Balance Sheet | |||||
| Total Assets | 12.17B | 12.39B | 13.56B | 14.13B | 15.00B |
| Cash, Cash Equivalents and Short-Term Investments | 919.87M | 1.16B | 1.60B | 454.36M | 603.32M |
| Total Debt | 3.52B | 3.33B | 4.07B | 4.60B | 5.16B |
| Total Liabilities | 4.92B | 4.73B | 5.69B | 6.75B | 7.86B |
| Stockholders Equity | 7.25B | 7.67B | 7.87B | 7.38B | 7.14B |
Cash Flow | |||||
| Free Cash Flow | 508.25M | 541.65M | 9.90M | 594.18M | 1.32B |
| Operating Cash Flow | 581.78M | 628.30M | 91.27M | 679.81M | 1.41B |
| Investing Cash Flow | -17.35M | 776.16M | 1.31B | -132.85M | -4.11B |
| Financing Cash Flow | -855.05M | -1.13B | -947.12M | -661.80M | 2.94B |
Revvity Technical Analysis
Positive
93.96
Price Trends
92.47
Positive
98.14
Negative
94.77
Negative
Market Momentum
0.21
Negative
57.68
Neutral
67.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVTY, the sentiment is Positive. The current price of 93.96 is above the 20-day moving average (MA) of 88.83, above the 50-day MA of 92.47, and below the 200-day MA of 94.77, indicating a neutral trend. The MACD of 0.21 indicates Negative momentum. The RSI at 57.68 is Neutral, neither overbought nor oversold. The STOCH value of 67.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RVTY.
Revvity Risk Analysis
Revvity disclosed 24 risk factors in its most recent earnings report. Revvity reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Revvity Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $21.17B | 34.48 | 33.99% | ― | 1.25% | ― | |
70 Outperform | $21.20B | 21.39 | 13.88% | 1.80% | 11.03% | 14.34% | |
65 Neutral | $7.00B | 22.80 | 11.85% | 3.31% | 5.65% | 411.58% | |
62 Neutral | $9.67B | 27.94 | 3.24% | 0.29% | 3.67% | -12.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $11.96B | -25.57 | 164.85% | ― | 32.88% | 6.77% |
* Healthcare Sector Average
RVTY
Revvity
86.51
-3.65
-4.05%
ILMN
Illumina
139.37
64.84
87.00%
QGEN
Qiagen
33.96
-8.06
-19.18%
DGX
Quest Diagnostics
191.50
18.51
10.70%
GH
Guardant Health
91.17
49.24
117.43%
Revvity Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Revvity Posts Strong Q1 Results and Updates 2026 Outlook
Positive
May 5, 2026
Revvity reported first-quarter 2026 results on May 5, 2026, with revenue rising to $711 million from $665 million a year earlier and GAAP EPS from continuing operations improving to $0.37 from $0.35. Adjusted EPS from continuing operations increas...
Executive/Board ChangesShareholder Meetings
Revvity Shareholders Approve Governance Changes and Board Slate
Positive
May 1, 2026
At its April 28, 2026 annual meeting, Revvity shareholders elected ten directors to one-year terms and ratified Deloitte Touche LLP as the independent public accounting firm for the current fiscal year. Investors also approved, on a non-binding b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.